Literature DB >> 18775028

Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells.

Volker Kunzmann1, Brigitte Kimmel, Thomas Herrmann, Hermann Einsele, Martin Wilhelm.   

Abstract

Tumour growth promotes the expansion of CD4(+) CD25(+) FoxP3(+) regulatory T cells (Tregs) which suppress various arms of immune responses and might therefore contribute to tumour immunosurveillance. In this study, we found an inverse correlation between circulating Treg frequencies and phosphoantigen-induced gammadelta T-cell proliferation in cancer patients, which prompted us to address the role of Tregs in controlling the gammadelta T-cell arm of innate immune responses. In vitro, human Treg-peripheral blood mononuclear cell (PBMC) co-cultures strongly inhibited phosphoantigen-induced proliferation of gammadelta T cells and depletion of Tregs restored the impaired phosphoantigen-induced gammadelta T-cell proliferation of cancer patients. Tregs did not suppress other effector functions of gammadelta T cells such as cytokine production or cytotoxicity. Our experiments indicate that Tregs do not mediate their suppressive activity via a cell-cell contact-dependent mechanism, but rather secrete a soluble non-proteinaceous factor, which is independent of known soluble factors interacting with amino acid depletion (e.g. arginase-diminished arginine and indolamine 2,3-dioxygenase-diminished tryptophan) or nitric oxide (NO) production. However, the proliferative activity of alphabeta T cells was not affected by this cell-cell contact-independent suppressive activity induced by Tregs. In conclusion, these findings indicate a potential new mechanism by which Tregs can specifically suppress gammadelta T cells and highlight the strategy of combining Treg inhibition with subsequent gammadelta T-cell activation to enhance gammadelta T cell-mediated immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775028      PMCID: PMC2632687          DOI: 10.1111/j.1365-2567.2008.02894.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  51 in total

1.  Gamma/delta T-cell stimulation by pamidronate.

Authors:  V Kunzmann; E Bauer; M Wilhelm
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

Review 2.  Regulatory T cells: friend or foe in immunity to infection?

Authors:  Kingston H G Mills
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

3.  CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.

Authors:  F Poccia; B Cipriani; S Vendetti; V Colizzi; Y Poquet; L Battistini; M López-Botet; J J Fournié; M L Gougeon
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

4.  Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons.

Authors:  S Boullier; Y Poquet; T Debord; J J Fournie; M L Gougeon
Journal:  Eur J Immunol       Date:  1999-01       Impact factor: 5.532

5.  Gammadelta T-lymphocyte cytotoxic activity against Mycobacterium bovis analyzed by flow cytometry.

Authors:  Michael R Olin; K Hwa Choi; Jinhee Lee; Thomas W Molitor
Journal:  J Immunol Methods       Date:  2004-11-12       Impact factor: 2.303

6.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

7.  Vgamma9/Vdelta2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis.

Authors:  H Jomaa; J Feurle; K Lühs; V Kunzmann; H P Tony; M Herderich; M Wilhelm
Journal:  FEMS Immunol Med Microbiol       Date:  1999-09

8.  Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors.

Authors:  F Halary; M A Peyrat; E Champagne; M Lopez-Botet; A Moretta; L Moretta; H Vié; J J Fournié; M Bonneville
Journal:  Eur J Immunol       Date:  1997-11       Impact factor: 5.532

9.  Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons.

Authors:  F Poccia; S Boullier; H Lecoeur; M Cochet; Y Poquet; V Colizzi; J J Fournie; M L Gougeon
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

10.  Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells.

Authors:  Leonie S Taams; Jocea M R van Amelsfort; Machteld M Tiemessen; Kim M G Jacobs; Esther C de Jong; Arne N Akbar; Johannes W J Bijlsma; Floris P J G Lafeber
Journal:  Hum Immunol       Date:  2005-03       Impact factor: 2.850

View more
  25 in total

Review 1.  Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Authors:  Barbara Castella; Candida Vitale; Marta Coscia; Massimo Massaia
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 2.  Dynamics of the interaction of γδ T cells with their neighbors in vivo.

Authors:  Immo Prinz
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 3.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 4.  How tumors might withstand γδ T-cell attack.

Authors:  Aude-Hélène Capietto; Ludovic Martinet; Jean-Jacques Fournié
Journal:  Cell Mol Life Sci       Date:  2011-05-06       Impact factor: 9.261

Review 5.  Immune regulation of bone metastasis.

Authors:  Aude-Hélène Capietto; Roberta Faccio
Journal:  Bonekey Rep       Date:  2014-12-03

Review 6.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

7.  Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APCMin/+ mice.

Authors:  Louis Szeponik; Paulina Akeus; William Rodin; Sukanya Raghavan; Marianne Quiding-Järbrink
Journal:  Cancer Immunol Immunother       Date:  2020-03-17       Impact factor: 6.968

8.  Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

Authors:  A J Nicol; H Tokuyama; S R Mattarollo; T Hagi; K Suzuki; K Yokokawa; M Nieda
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

9.  Standardized astragalus extract for attenuation of the immunosuppression induced by strenuous physical exercise: randomized controlled trial.

Authors:  Ewa Latour; Jaroslaw Arlet; Emilia E Latour; Artur Juszkiewicz; Karolina Łuczkowska; Anita Marcinkiewicz; Piotr Basta; Jerzy Trzeciak; Bogusław Machaliński; Anna Skarpańska-Stejnborn
Journal:  J Int Soc Sports Nutr       Date:  2021-07-16       Impact factor: 5.150

10.  A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.

Authors:  Aurélie Thedrez; Vincent Lavoué; Benoit Dessarthe; Pascale Daniel; Sébastien Henno; Isabelle Jaffre; Jean Levêque; Véronique Catros; Florian Cabillic
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.